Liquidia Corporation Common Stock
Compare this stock
LQDA Stock Report Card
$
46%
Performance
Score:
100/100
LQDA returned 32.09% in the last 12 months. Based on SPY's performance of -13.52%, its performance is above average giving it a score of 100 of 100.
Analyst Price Targets
Score:
88/100
4 analysts offer 12-month price targets for LQDA. Together, they have an average target of 12, the most optimistic target put LQDA at 17 within 12-months and the most pessimistic has LQDA at 3.
Sentiment
Score:
68/100
LQDA had a bullish sentiment score of 67.78% across Twitter and StockTwits over the last 12 months. It had an average of 2.48 posts, 3.23 comments, and 3.61 likes per day.
Technicals
Score:
29/100
LQDA receives a 28 of 100 based on 14 indicators. 3 are bullish, 9 are bearish.
Earnings
Score:
10/100
LQDA has missed earnings 11 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 20 quarters, LQDA has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
48/100
LQDA has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.
Liquidia Corporation Common Stock Summary
Nasdaq / LQDA
Healthcare
Biotechnology
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
LQDA scored poorly on our reportcard. Here are some similar companies and how they performed.
